COVID 19
Conditions
Brief summary
Metabolomics is the analysis of small molecules in a biological sample (cells, tissues or biological fluids). It can potentially detect very sensitively any change related to a pathology or exposure to a toxic agent. The analyses are fast, inexpensive and therefore applicable in routine, particularly in health care. Given the emergence of this new disease, COVID-19, there is a real need to better understand the pathophysiological mechanisms of SARS-CoV-2 infection. In this context, metabolomics could have a place and could lead to the development of interesting diagnostic or prognostic tools. The objective of this study is to identify, through the analysis of biological samples (blood and urine), whether there is a metabolomic signature in patients with COVID-19.
Interventions
OTHERCOVID-19 patients
It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Patient with COVID-19 disease
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patient over 18 years of age * affiliated to a social security scheme * consultant in the emergency department and/or being hospitalized for suspected SARS CoV infection * confirmation, after medical examination, of the need for a biological examination (this will negate the need for additional venipuncture)
Exclusion criteria
* Patient who do not meet inclusion criteria * Person subject to a guardianship order * Opposition to the use of the data or samples (withdrawal of non-opposition) / Sponsor's or investigator's decision
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identifying the metabolomic signature | Enrollment | To dentified a metabolomic profile using liquid chromatography combined with mass spectrometry (LC-MS) on the serum and urine of COVID-19 patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identification of the metabolomic profile according to clinical severity. | Enrollment | Identification of the metabolomic profile of patients infected with SARS CoV 2 in the following subgroups: pauci-symptomatic patients, symptomatic patients without clinical severity criteria, and critically ill COVID-19 patients. |
Countries
France
Outcome results
None listed